Drug Allergy pp 343-367 | Cite as

Contrast Media

  • Brian A. Baldo
  • Nghia H. Pham


Reactions to iodinated contrast media range from mild inconvenience to life-threatening emergency. Histamine release can account for many of the symptoms and nonionic agents are tolerated better than ionics. Reactions can be immediate (IR) or delayed (DR). Incidences of the former are 3–4 % (ionics), 0.2–0.7 % (non-ionics), severe reactions 0.1–0.4 % (ionics), and 0.02–0.04 % (non-ionics). Up to 80 % of reactions can be avoided by using nonionic agents. For DRs, there is no difference between the incidences of reactions to each of the agents. Risk factors for IRs are a previous reaction to a contrast medium, bronchial asthma, cardiac disease, and highly allergic subjects; for DRs, a previous reaction, use of β-blockers, treatment with IL-2, history of drug allergy, and contact allergy. Diagnosis of IRs is based largely on skin tests; IgE antibodies have not been convincingly demonstrated. Breakthrough reactions have occurred following corticosteroid and H1 antagonist premedication. Gadolinium-based agents, especially the linear chelates, have been associated with nephrogenic systemic fibrosis. They show an adverse reaction incidence of about 0.48 % and 0.01 % for anaphylaxis. Overall, given the large number of contrast media administered, they are one of the safest drugs.


Contrast Medium Iodinate Contrast Medium Iodine Atom Nephrogenic Systemic Fibrosis Gadopentetate Dimeglumine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Further Reading

  1. ACR manual on contrast media, version 7. ACR committee on drugs and contrast media. American College of Radiology; 2010Google Scholar
  2. Brockow K, Romano A, Aberer W, et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media – a European multicenter study. Allergy. 2009;64:234–41.PubMedCrossRefGoogle Scholar
  3. Caravan P, Ellison JJ, McMurry TJ, et al. Gadolinium (III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99:2293–352.PubMedCrossRefGoogle Scholar
  4. ESUR guidelines on contrast media. European society of urogenital radiology, version 7.0 view.
  5. Morcos SK. Acute serious and fatal reactions to contrast media: our current understanding. Br J Radiol. 2005;78:686–93.PubMedCrossRefGoogle Scholar
  6. Murphy KJ, Brunberg JA, Cohan RH. Adverse reactions to gadolinium contrast media: a review of 36 cases. AJR Am J Roentgenol. 1996;167:847–9.PubMedCrossRefGoogle Scholar
  7. Prince MR, Zhang H, Zou Z, et al. Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol. 2011;196:W138–43.PubMedCrossRefGoogle Scholar
  8. Thomsen HS. ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol. 2007;17:2692–6.PubMedCrossRefGoogle Scholar
  9. Thomsen HS. Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin North Am. 2009;47:827–31.PubMedCrossRefGoogle Scholar
  10. Trcka J, Schmidt C, Seitz CS, et al. Anaphylaxis to iodinated contrast material: nonallergic hypersensitivity or IgE-mediated allergy? AJR Am J Roentgenol. 2008; 190:666–70.PubMedCrossRefGoogle Scholar
  11. Webb JAW, Stacul F, Thomsen HS, et al. Late adverse reactions to intravascular iodinated contrast media. Eur Radiol. 2003;13:181–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  • Brian A. Baldo
    • 1
  • Nghia H. Pham
    • 1
  1. 1.Formerly-Molecular Immunology Unit Kolling Institute of Medical ResearchRoyal North Shore Hospital of SydneySydneyAustralia

Personalised recommendations